Cannabinoid Encyclopedia

Focused research review

NADA: what the research says

What evidence defines NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms?

Updated July 2026 13 research sources Mostly early-stage research

The short answer

What is the bottom line?

Research has examined NADA. This page brings together 7 human-study sources, 1 research review, and 5 lab, animal, or mechanism sources. Most of the current evidence is preclinical or focused on biological mechanisms. The studies do not all test the same product, dose, group of people, or outcome, so they cannot be reduced to one answer for every person or product. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about NADA.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on NADA covers NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, o...; those areas should not be combined into one claim. 1

  2. 2

    Most of the current evidence is preclinical or focused on biological mechanisms. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about NADA

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Mostly mechanism-focused

NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, o...

This part of the literature focuses on NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, o.... Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 2

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

7 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

1 source

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

5 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on NADA is not one kind of study. This source set includes 7 animal studies, 5 cell or laboratory studies, and 1 narrative or expert review. 3

The recorded populations or models include people or patients (7 sources), animal models (4 sources), and cells or tissue models (2 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is nADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms (13 sources). Closely related outcome names can still describe different measurements. 5

The NADA source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

animal study

Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret.

On this page, this source examines NADA and nADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms. 1

Study type
animal study
Population or model
animal models
Outcome focus
nADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms
Evidence stage
mechanism-focused research

animal study

TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat.

On this page, this source examines NADA and nADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms. 2

Study type
animal study
Population or model
people or patients
Outcome focus
nADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms
Evidence stage
mechanism-focused research

narrative or expert review

N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities.

On this page, this source examines NADA and nADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms. 3

Study type
narrative or expert review
Population or model
cells or tissue models
Outcome focus
nADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms
Evidence stage
evidence still limited

animal study

Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels.

On this page, this source examines NADA and nADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms. 4

Study type
animal study
Population or model
people or patients
Outcome focus
nADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms
Evidence stage
mechanism-focused research

animal study

Endovanilloids are potential activators of the trigeminovascular nocisensor complex.

On this page, this source examines NADA and nADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms. 5

Study type
animal study
Population or model
animal models
Outcome focus
nADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms
Evidence stage
mechanism-focused research

Safety and limits

What should readers keep in mind?

Research on NADA should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What evidence defines NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms?

Relevant research is collected here. Most of the current evidence is preclinical or focused on biological mechanisms. 7

Why is there not always a yes-or-no answer?

The sources may test different products, doses, people, and outcomes, so a single conclusion can hide important differences. 8

Where can I read the original studies?

Use the numbered citations and the source list at the bottom of the page to open PubMed or DOI records. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. animal study; mechanism-focused research PubMed 17459108 DOI 10.1111/j.1460-9568.2007.05521.x
  2. 2
    TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat. animal study; mechanism-focused research PubMed 15245490 DOI 10.1111/j.1460-9568.2004.03481.x
  3. 3
    N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities. narrative or expert review; evidence still limited PubMed 29082315 DOI 10.1089/can.2017.0015
  4. 4
    Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. animal study; mechanism-focused research PubMed 15289293 DOI 10.1038/sj.bjp.0705924
  5. 5
    Endovanilloids are potential activators of the trigeminovascular nocisensor complex. animal study; mechanism-focused research PubMed 27189587 DOI 10.1186/s10194-016-0644-7
  6. 6
    Increased depressor response to N-arachidonoyl-dopamine during high salt intake: role of the TRPV1 receptor. animal study; mechanism-focused research PubMed 17984664 DOI 10.1097/hjh.0b013e3282efd1bf
  7. 7
    Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. animal study; mechanism-focused research PubMed 15006899 DOI 10.1038/sj.bjp.0705711
  8. 8
    N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1. animal study; mechanism-focused research PubMed 28701511 DOI 10.4049/jimmunol.1602151
  9. 9
    A cannabinoid receptor agonist N-arachidonoyl dopamine inhibits adipocyte differentiation in human mesenchymal stem cells. cell or laboratory study; mechanism-focused research PubMed 25995819 DOI 10.4062/biomolther.2014.137
  10. 10
    Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel. cell or laboratory study; mechanism-focused research PubMed 33568652 DOI 10.1038/s41467-021-20946-6
  11. 11
    N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. cell or laboratory study; mechanism-focused research PubMed 16760924 DOI 10.1038/sj.npp.1301118
  12. 12
    Pharmacology of capsaicin-, anandamide-, and N-arachidonoyl-dopamine-evoked cell death in a homogeneous transient receptor potential vanilloid subtype 1 receptor population. cell or laboratory study; mechanism-focused research PubMed 20354008 DOI 10.1093/bja/aeq067
See all 13 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities. narrative or expert review; evidence still limited / 1 linked research note PubMed 29082315
  2. TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat. animal study; mechanism-focused research / 1 linked research note PubMed 15245490
  3. Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. animal study; mechanism-focused research / 1 linked research note PubMed 17459108
  4. The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 24644287
  5. Endovanilloids are potential activators of the trigeminovascular nocisensor complex. animal study; mechanism-focused research / 1 linked research note PubMed 27189587
  6. Pharmacology of capsaicin-, anandamide-, and N-arachidonoyl-dopamine-evoked cell death in a homogeneous transient receptor potential vanilloid subtype 1 receptor population. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 20354008
  7. Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. animal study; mechanism-focused research / 1 linked research note PubMed 15289293
  8. Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. animal study; mechanism-focused research / 1 linked research note PubMed 15006899
  9. A cannabinoid receptor agonist N-arachidonoyl dopamine inhibits adipocyte differentiation in human mesenchymal stem cells. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 25995819
  10. N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1. animal study; mechanism-focused research / 1 linked research note PubMed 28701511
  11. N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 16760924
  12. Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 33568652
  13. Increased depressor response to N-arachidonoyl-dopamine during high salt intake: role of the TRPV1 receptor. animal study; mechanism-focused research / 1 linked research note PubMed 17984664